Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (77)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Daly, E
Right arrow Articles by Vessey, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Daly, E
Right arrow Articles by Vessey, M
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

British Medical Bulletin 48:368-400 (1992)
© 1992 The British Council

research-article

HRT: An analysis of benefits, risks and costs

E Daly, M Roche, D Barlow, A Gray, K McPherson and M Vessey

Oxford Hormone Replacement Therapy Study Group, Department of Public Health & Primary Care, University of Oxford Oxford, UK

Abstract

A cost-effectiveness analysis of hormone replacement therapy (HRT) was undertaken to assess the relative benefits of different treatment strategies, and to identify which factors most influence cost-effectiveness. The current lack of conclusive evidence on the effects of HRT, especially in relation to combined therapy and cardiovascular disease, necessitated the use of a large number of assumptions in our model. In terms of net health benefits, the potential reduction in cardiovascular disease would have greatest impact, and would overshadow any small increase in breast cancer risk possibly associated with long-term use. Net expenditure by the NHS will depend critically on the direct costs of treatment, rather than on any indirect costs incurred or averted as a result of side-effects. In terms of cost-effectiveness, long-term prophylactic treatment of hysterectomised women and treatment of symptomatic women with a uterus compare favourably with other accepted health care interventions.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 BMJHome page
T. B Gosden and D. J Torgerson
Economics notes: Converting international cost effectiveness data to UK prices
BMJ, August 3, 2002; 325(7358): 275 - 276.
[Full Text] [PDF]

Home page
 Hum ReprodHome page
D.H. Barlow
Cost-effectiveness modelling
Hum. Reprod., December 1, 2001; 16(12): 2479 - 2480.
[Full Text] [PDF]

Home page
 NEJMHome page
D. Hosking, C. E.D. Chilvers, C. Christiansen, P. Ravn, R. Wasnich, P. Ross, M. McClung, A. Balske, D. Thompson, M. Daley, et al.
Prevention of Bone Loss with Alendronate in Postmenopausal Women under 60 Years of Age
N. Engl. J. Med., February 19, 1998; 338(8): 485 - 492.
[Abstract] [Full Text] [PDF]

Home page
 Arch Intern MedHome page
D. J. Torgerson, R. E. Thomas, M. K. Campbell, and D. M. Reid
Randomized Trial of Osteoporosis Screening: Use of Hormone Replacement Therapy and Quality-of-Life Results
Arch Intern Med, October 13, 1997; 157(18): 2121 - 2125.
[Abstract] [PDF]

Home page
 BMJHome page
T. Marshall
Hormone replacement therapy for all?
BMJ, November 9, 1996; 313(7066): 1205c - 1205.
[Full Text]

Home page
 BMJHome page
S. Panico, R. Galasso, E. Celentano, L. Frova, R. Capocaccia, and F. Berrino
Hormone replacement therapy may not always be right choice to prevent cardiovascular disease
BMJ, September 14, 1996; 313(7058): 687 - 687.
[Full Text]

Home page
 BMJHome page
A J Isaacs, A R Britton, and K. McPherson
Utilisation of hormone replacement therapy by women doctors
BMJ, November 25, 1995; 311(7017): 1399 - 1401.
[Abstract] [Full Text]

Home page
 Arch Intern MedHome page
N. M. Kaplan
The Treatment of Hypertension in Women
Arch Intern Med, March 27, 1995; 155(6): 563 - 567.
[Abstract] [PDF]

Home page
 BMJHome page
F French, D Torgerson, and R W Porter
Overestimation of cost savings: in prevention of osteoporosis
BMJ, January 8, 1994; 308(6921): 138 - 138.
[Full Text]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.